Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years 5 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula
BRIEF

published on 04/25/2024 at 13:05, 2 years 6 months ago

Moderna to Present Diverse Research Studies at ESCMID Global Congress

COVID-19 Vaccine Moderna Vaccine Research Influenza Vaccine ESCMID Congress
PRESS RELEASE

published on 04/25/2024 at 13:00, 2 years 6 months ago

Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Moderna, Inc. to present data on COVID-19, influenza, respiratory syncytial virus, and cytomegalovirus vaccines at ESCMID Global Congress in Barcelona, Spain

COVID-19 Moderna Inc. Barcelona Vaccines ESCMID Global Congress
BRIEF

published on 04/24/2024 at 14:05, 2 years 6 months ago

Moderna Collaborates with OpenAI to Enhance mRNA Medicines Using Advanced AI

Healthcare Innovation MRNA Technology Moderna OpenAI AI Collaboration
PRESS RELEASE

published on 04/24/2024 at 14:00, 2 years 6 months ago

Moderna and OpenAI Collaborate To Advance mRNA Medicine
Moderna and OpenAI collaborate to integrate generative AI tools, like ChatGPT Enterprise, into operations to enhance AI culture and augment employee roles for maximum impact on patients

Generative AI Machine Learning Moderna OpenAI ChatGPT Enterprise
BRIEF

published on 04/17/2024 at 13:05, 2 years 6 months ago

Moderna to Present Q1 2024 Financial Results in May

Financial Results Conference Call Webcast Moderna Q1 2024
PRESS RELEASE

published on 04/17/2024 at 13:00, 2 years 6 months ago

Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Moderna, Inc. will host a live conference call to report Q1 2024 financial results and provide a corporate update. Moderna is a leader in mRNA medicine revolutionizing disease treatment

Financial Results Conference Call Corporate Update Moderna Inc. MRNA Medicine
BRIEF

published on 04/03/2024 at 17:05, 2 years 6 months ago

Moderna's mRNA Therapy for Propionic Acidemia Shows Promise in Early-Stage Trial

Gene Therapy Clinical Trial Moderna MRNA Therapy Propionic Acidemia
PRESS RELEASE

published on 04/03/2024 at 17:00, 2 years 6 months ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Moderna, Inc. announced interim data for mRNA-3927 therapy for propionic acidemia published in Nature, showing signs of clinical benefit and safety. Ongoing global trial evaluates safety and efficacy in participants with PA

Clinical Trial Moderna Propionic Acidemia MRNA-3927 Genetic Disorder
BRIEF

published on 03/27/2024 at 11:35, 2 years 7 months ago

Moderna Announces Significant Advancements in Vaccine Development Programs

COVID-19 MRNA Technology Moderna Vaccine Development Phase 3 Clinical Trials

Published on 10/30/2026 at 23:35, 1 day 19 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 19 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 1 day 22 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 1 day 23 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 3 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 11/01/2026 at 10:35, 8 hours 12 minutes ago

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 13 hours 47 minutes ago

2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 2 hours ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 19 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 22:30, 1 day 20 hours ago

/C O R R E C T I O N - OCI Global/

View all EQS

Published on 10/30/2026 at 23:00, 1 day 19 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 1 day 22 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 2 days ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 6 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 2 days 10 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News